<DOC>
	<DOCNO>NCT00611026</DOCNO>
	<brief_summary>To evaluate efficacy safety fesoterodine comparison tolterodine placebo overactive bladder</brief_summary>
	<brief_title>Clinical Trial Evaluate Efficacy Safety Fesoterodine Comparison Tolterodine Extended Release ( ER ) Patients With Overactive Bladder .</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Adult subject overactive bladder symptom ( subjectreported ) great equal 3 month prior Screening/Enrollment visit . Reported least average 1 UUI episode per 24 hour 3day bladder diary prior Randomization/Baseline visit Mean urinary frequency great equal 8 micturition per 24 hour verify 3day bladder diary prior randomization/Baseline visit . Subjects condition would contraindicate usage fesoterodine include : hypersensitivity active substance ( fesoterodine fumarate ) peanut soya excipients , urinary retention , gastric retention , uncontrolled narrow angle glaucoma , myasthenia gravis , severe hepatic impairment ( Child Pugh C ) , severe ulcerative colitis , toxic megacolon . Subjects clinically significant hepatic renal disease significant unstable disease . OAB symptom cause neurological condition , know pathology urinary tract , etc . Subjects previous history acute urinary retention require catheterization , severe void difficulty judgment investigator , prior baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Treatment overactive bladder</keyword>
</DOC>